申请人：——
公开号：US20020022652A1
公开（公告）日：2002-02-21
A method of treatment of a host with a cellular proliferative disease, comprising contacting the host with a methylnogarol and an antiproliferative agent, each in an amount sufficient to modulate said cellular proliferative disease, is described. In some embodiments the methylnogarol comprises menogaril (7-O-Methylnogarol; 7-Con-O-Methylnogarol; U-52047; 2,6-Epoxy-2H-naphthaceno[1,2-b]oxocin-9,16-dione, 4-(dimethylamino)-3,4,5,6,11,12,13,14-octahydro-3,5,8,10,13-pentahydroxy-11-methoxy-6,13 -dimethyl, -(2alpha,3beta,4alpha,5beta,6alpha, 11 alpha, 13alpha)-, (P)-; 2,6-Epoxy-2H-naphthaceno[1,2-b]oxocin-9,16-dione,4-(dimethylamino)-3,4,5,6,11,12,13,14-octahydro-3,5,8,10,13-pentahydroxy-11-methoxy-6,13-dimethyl-; 7(R)-O-Methylnogarol; 7-OMEN). Antiproliferative agents of the invention comprise alkylating agents, intercalating agents, metal coordination complexes, pyrimidine nucleosides, purine nucleosides, inhibitors of nucleic acid associated enzymes and proteins, and agents affecting structural proteins and cytoplasmic enzymes. The invention comprises the described methods as well as compositions comprising a methylnogarol and an antiproliferative agent.
本文描述了一种治疗患有细胞增殖性疾病的宿主的方法，该方法包括使宿主与一种甲基诺加洛尔和一种抗增殖剂接触，每种物质的量都足以调节所述细胞增殖性疾病。在一些实施方案中，甲基诺卡洛包括 menogaril (7-O-Methylnogarol; 7-Con-O-Methylnogarol; U-52047; 2,6-Epoxy-2H-naphthaceno[1,2-b&rsqb；肟-9,16-二酮, 4-(二甲基氨基)-3,4,5,6,11,12,13,14-八氢-3,5,8,10,13-五羟基-11-甲氧基-6,13-二甲基, -(2α,3β,4α,5β,6α, 11α, 13α)-, (P)-；2,6-Epoxy-2H-naphthaceno[1,2-b]oxocin-9,16-dione,4-(dimethylamino)-3,4,5,6,11,12,13,14-octahydro-3,5,8,10,13-pentahydroxy-11-methoxy-6,13-dimethyl-; 7(R)-O-Methylnogarol; 7-OMEN).本发明的抗增殖剂包括烷化剂、插层剂、金属配位络合物、嘧啶核苷、嘌呤核苷、核酸相关酶和蛋白质的抑制剂，以及影响结构蛋白和细胞质酶的制剂。本发明包括所述方法以及包含甲基诺卡洛和抗增殖剂的组合物。
